← All trials
NCT04233151
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 590
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.